The present invention intends to provide a non-human animal model of Guillain-Barre syndrome, which can be obtained by immunizing Fc.gamma.RIIB-gene-deficient non-human animal with ganglioside GQ1b, and a screening method of a therapeutic agent for Guillain-Barre syndrome using the non-human animal model. A mouse model of Guillain-Barre syndrome is generated by immunizing Fc.gamma.RIIB-gene-deficient mice with gangliosides GM1, GM2, GD1a, and GQ1b together with Freund's adjuvant every three weeks four times in total.